Tina Gaskin
Family · Daytona Beach, FLNPI 1235463266
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 115 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 23.9% — the pattern of someone who eats at a lot of different presentations.
Across 115 payments — averaging $20.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$562
- Novo Nordisk$494
- Lilly USA, LLC$295
- Exact Sciences$177
- Boehringer Ingelheim$157
- Pfizer$156
- plus $509 from 9 others
Across 18 payments — averaging $2049.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$37K
What the payments were for
- Food & beverage$2,349100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 25 | $562 |
| Novo Nordisk | 26 | $494 |
| Lilly USA, LLC | 17 | $295 |
| Exact Sciences | 7 | $177 |
| Boehringer Ingelheim | 8 | $157 |
| Pfizer | 7 | $156 |
| AbbVie | 5 | $115 |
| Teva Pharmaceuticals USA, Inc. | 4 | $80 |
| Sanofi-aventis U.S. LLC | 3 | $72 |
| Abbott | 3 | $54 |
| Bayer | 3 | $52 |
| Medtronic | 2 | $49 |
| GSK | 2 | $36 |
| Merck | 2 | $28 |
| Amgen | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$101
How this compares
$2,349 in reported general payments places this provider in the 80th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 211 | $253,499 |
| JardianceEmpagliflozin | 69 | $89,637 |
| FarxigaDapagliflozin Propanediol | 72 | $85,903 |
| OzempicSemaglutide | 60 | $85,899 |
| EliquisApixaban | 87 | $84,021 |
| TrulicityDulaglutide | 22 | $39,211 |
| JanuviaSitagliptin Phosphate | 27 | $38,751 |
| TradjentaLinagliptin | 14 | $20,083 |
| Tresiba Flextouch U-100Insulin Degludec | 34 | $18,859 |
| Bydureon BciseExenatide Microspheres | 16 | $18,592 |
| XareltoRivaroxaban | 13 | $18,114 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $17,077 |
| LinzessLinaclotide | 19 | $13,914 |
| Emgality PenGalcanezumab-Gnlm | 13 | $12,078 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 11 | $10,682 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $295 | $292,710233 claims |
| Boehringer IngelheimJardiance, Tradjenta | $157 | $109,72083 claims |
| AstraZenecaFarxiga, Symbicort | $562 | $94,25896 claims |
| Novo NordiskOzempic | $494 | $85,89960 claims |
| PfizerEliquis | $156 | $84,02187 claims |
| MerckJanuvia | $28 | $38,75127 claims |
| AbbVieLinzess, Synthroid | $115 | $15,48435 claims |
| GSKBreo Ellipta, Incruse Ellipta | $36 | $12,07227 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $72 | $10,68211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 14,618 family providers in Florida.
Other family in Daytona Beach
- Lewis HarringtonTampa$954K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
- Deena RodneyMaitland$323K
- Yamila MelendezMiami$212K
- Holly BoydLand O Lakes$200K
- Rachael BuschLoxahatchee$189K
- Victor Tatis de la NuezMiramar$161K
- Ronda CrewsJax Bch$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.